Sep 5, 2023
Mark McDonough, the CEO of ChromaCode, is leveraging high-definition PCR testing to overcome the limitations of conventional PCR to identify biomarkers of infectious diseases and cancer. While gene sequencing can provide valuable information, it requires more tissue, is expensive, and requires at least a week for...
Sep 5, 2023
Mark McDonough, the CEO of ChromaCode, is leveraging high-definition PCR testing to overcome the limitations of conventional PCR to identify biomarkers of infectious diseases and cancer. While gene sequencing can provide valuable information, it requires more tissue, is expensive, and requires at least a week for...